OKAY
833230
CHANGFU CO.,LTD
871396
CHENGUANG MEDICAL
430300
Gansu Longshenrongfa Pharmaceutical Industry
300534
Tibet Duo Rui Pharmaceutical
301075
CN Stock MarketDetailed Quotes
688373 Shanghai Micurx Pharmaceutical
- 6.08
- +0.29+5.01%
Noon Break Apr 1 11:29 CST
3.99BMarket Cap-9.05P/E (TTM)
6.15High5.82Low78.96KlotVolume5.86Open5.79Pre Close47.59MTurnover2.16%Turnover RatioLossP/E (Static)655.61MShares6.6952wk High9.07P/B2.23BFloat Cap3.6852wk Low6.95Limit Up366.05MShs Float14.20Historical High4.63Limit Down5.70%Amplitude3.23Historical Low--Dividend TTM6.03Avg Price35.70KlotAsk--Div YieldTTM100Lot Size41.89KlotBid
Shanghai Micurx Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 43.51%130.27M | 42.90%97.56M | 44.24%60.74M | 91.10%33.02M | 88.31%90.78M | 95.87%68.27M | 106.60%42.11M | 61.66%17.28M | 529.33%48.21M | 534.91%34.86M |
| Operating revenue | 43.51%130.27M | 42.90%97.56M | 44.24%60.74M | 91.10%33.02M | 88.31%90.78M | 95.87%68.27M | 106.60%42.11M | 61.66%17.28M | 529.33%48.21M | 534.91%34.86M |
| Total operating cost | 8.01%581.6M | 17.60%394.74M | 44.73%267.53M | 68.53%140.53M | 70.60%538.48M | 49.64%335.65M | 38.65%184.85M | 26.40%83.38M | 12.75%315.65M | 33.20%224.31M |
| Operating cost | 34.20%22.41M | 38.67%17.34M | 42.78%11.23M | 72.03%5.81M | 89.25%16.7M | 99.08%12.5M | 120.36%7.87M | 112.70%3.38M | 1,425.32%8.82M | 2,348.19%6.28M |
| Operating tax surcharges | 37.60%407.66K | -44.68%89.87K | -44.59%66.18K | 16.13%68.5K | 117.40%296.27K | 25.90%162.45K | 24.97%119.44K | 1,081.56%58.98K | 306.73%136.28K | 2,419.78%129.03K |
| Operating expense | 2.87%110.49M | 17.97%81.58M | 17.79%52.69M | 96.83%30.29M | 30.16%107.41M | 31.88%69.16M | 42.98%44.73M | 1.14%15.39M | 24.62%82.52M | 38.48%52.44M |
| Administration expense | 8.39%66.3M | 1.24%43.88M | 4.01%31.29M | -0.95%16.84M | -3.91%61.17M | -8.68%43.34M | 5.65%30.09M | 16.89%17M | 9.45%63.66M | 13.19%47.46M |
| Financial expense | 66.76%13.43M | 0.81%7.6M | 2.22%6.09M | -29.68%2.88M | -20.41%8.06M | 146.54%7.54M | 36.80%5.95M | 140.16%4.09M | 214.81%10.12M | 78.54%3.06M |
| -Interest expense (Financial expense) | 10.03%11.15M | 22.91%9.08M | -5.90%5.02M | 2.86%1.23M | 14.97%10.14M | 16.84%7.39M | 20.97%5.33M | -46.59%1.19M | 68.50%8.82M | 99.53%6.32M |
| -Interest Income (Financial expense) | -8.41%-2.37M | -26.22%-1.88M | -85.35%-1.66M | -172.44%-1.22M | 50.33%-2.19M | 60.43%-1.49M | 26.47%-894.82K | 29.45%-449.07K | -83.74%-4.4M | -131.17%-3.76M |
| Research and development | 6.87%368.56M | 20.35%244.25M | 72.91%166.17M | 94.73%84.65M | 129.31%344.86M | 76.57%202.95M | 46.61%96.1M | 32.06%43.47M | -0.90%150.39M | 32.69%114.94M |
| Credit Impairment Loss | -399.12%-1.64M | -27.00%-221.98K | -75.88%27.51K | -1,108.28%-98.62K | -233.10%-328.02K | -161.14%-174.79K | 172.39%114.06K | 108.12%9.78K | 172.49%246.45K | 92.84%285.88K |
| Other net revenue | ||||||||||
| Fair value change income | -48.77%17.08M | -56.38%11.83M | -53.79%9.93M | -45.62%5.29M | 80.32%33.34M | 140.40%27.13M | 618.25%21.49M | 362.67%9.73M | 75.61%18.49M | 36.50%11.29M |
| Asset deal income | 1,781.06%27.46K | ---- | ---- | ---- | -99.72%1.46K | -99.72%1.46K | -99.72%1.46K | ---- | --513.69K | --520.24K |
| Other revenue | -63.94%1.36M | 122.03%440.64K | 46.69%291.13K | -6.90%184.78K | -85.01%3.78M | 56.74%198.46K | 83.29%198.46K | 404.49%198.46K | 310.85%25.25M | -96.93%126.62K |
| Operating profit | -5.74%-434.49M | -18.69%-285.12M | -62.51%-196.54M | -81.85%-102.13M | -84.31%-410.9M | -35.54%-240.22M | -10.47%-120.94M | -6.49%-56.16M | 12.97%-222.94M | -17.73%-177.23M |
| Add:Non operating Income | ---- | --2.55K | ---- | ---- | ---- | ---- | ---- | ---- | -87.62%3.71M | -86.10%3.49M |
| Less:Non operating expense | -99.46%22.89K | -99.61%16.29K | -99.86%5.8K | --5.8K | 300.18%4.25M | 18,645.14%4.23M | 31,950.11%4.18M | ---- | 4,816.01%1.06M | 1,240.82%22.57K |
| Total profit | -4.66%-434.51M | -16.64%-285.13M | -57.09%-196.55M | -81.86%-102.14M | -88.45%-415.15M | -40.68%-244.45M | -16.13%-125.12M | -10.04%-56.16M | 2.62%-220.29M | -38.50%-173.77M |
| Less:Income tax cost | 3.99%6.21M | 109,690.81%6.16M | 85,725.30%4.76M | ---- | 110,872.86%5.97M | 6.18%5.61K | 6.87%5.54K | ---- | -86.15%5.38K | -86.42%5.29K |
| Net profit | -4.65%-440.72M | -19.16%-291.3M | -60.89%-201.3M | -81.86%-102.14M | -91.16%-421.12M | -40.68%-244.46M | -16.13%-125.12M | -10.04%-56.16M | 2.64%-220.3M | -38.47%-173.77M |
| Net profit from continuing operation | -4.65%-440.72M | -19.16%-291.3M | -60.89%-201.3M | -81.86%-102.14M | -91.16%-421.12M | -40.68%-244.46M | -16.13%-125.12M | -10.04%-56.16M | 2.64%-220.3M | -38.47%-173.77M |
| Net profit of parent company owners | -4.65%-440.72M | -19.16%-291.3M | -60.89%-201.3M | -81.86%-102.14M | -91.16%-421.12M | -40.68%-244.46M | -16.13%-125.12M | -10.04%-56.16M | 2.64%-220.3M | -38.47%-173.77M |
| Earning per share | ||||||||||
| Basic earning per share | -4.69%-0.67 | -18.92%-0.44 | -63.16%-0.31 | -77.78%-0.16 | -68.42%-0.64 | -19.35%-0.37 | 9.52%-0.19 | 10.00%-0.09 | 11.63%-0.38 | -29.17%-0.31 |
| Diluted earning per share | -4.69%-0.67 | -18.92%-0.44 | -63.16%-0.31 | -77.78%-0.16 | -68.42%-0.64 | -19.35%-0.37 | 9.52%-0.19 | 10.00%-0.09 | 11.63%-0.38 | -29.17%-0.31 |
| Other composite income | 66.26%6.18M | -85.03%1.62M | -64.62%4.3M | 115.40%673.64K | -55.01%3.71M | 84.20%10.84M | 403.06%12.15M | -4,068.42%-4.37M | 948.19%8.26M | 4,782.27%5.89M |
| Other composite income of parent company owners | 66.26%6.18M | -85.03%1.62M | -64.62%4.3M | 115.40%673.64K | -55.01%3.71M | 84.20%10.84M | 403.06%12.15M | -4,068.42%-4.37M | 948.19%8.26M | 4,782.27%5.89M |
| Total composite income | -4.11%-434.55M | -24.00%-289.67M | -74.38%-197.01M | -67.61%-101.46M | -96.85%-417.41M | -39.15%-233.62M | -7.25%-112.97M | -18.37%-60.54M | 6.69%-212.04M | -33.64%-167.89M |
| Total composite income of parent company owners | -4.11%-434.55M | -24.00%-289.67M | -74.38%-197.01M | -67.61%-101.46M | -96.85%-417.41M | -39.15%-233.62M | -7.25%-112.97M | -18.37%-60.54M | 6.69%-212.04M | -33.64%-167.89M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
